losartan genoptim 100 mg tabletki powlekane
synoptis pharma sp. z o.o. - losartanum kalicum - tabletki powlekane - 100 mg
levomine mini 20 mcg + 100 mcg tabletki powlekane
sun-farm sp. z o.o. - ethinylestradiolum + levonorgestrelum - tabletki powlekane - 20 mcg + 100 mcg
aurovalsart hct 320 mg + 12,5 mg tabletki powlekane
aurovitas pharma polska sp. z o.o. - valsartanum + hydrochlorothiazidum - tabletki powlekane - 320 mg + 12,5 mg
apo-atorva 30 mg tabletki powlekane
aurovitas pharma polska sp. z o.o. - atorvastatinum calcicum trihydricum - tabletki powlekane - 30 mg
apo-atorva 60 mg tabletki powlekane
aurovitas pharma polska sp. z o.o. - atorvastatinum calcicum trihydricum - tabletki powlekane - 60 mg
paracetamol polfa-Łódź 500 mg tabletki
urgo sp. z o.o. - paracetamolum - tabletki - 500 mg
vumerity
biogen netherlands b.v. - diroximel fumarate (biib098) - stwardnienie rozsiane, Рецидивно-znika - leki immunosupresyjne - vumerity is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis (see section 5. 1 for important information on the populations for which efficacy has been established).
teriflunomide mylan
mylan pharmaceuticals limited - teriflunomide - stwardnienie rozsiane, Рецидивно-znika - leki immunosupresyjne - teriflunomide mylan is indicated for the treatment of adult patients and paediatric patients aged 10 years and older (body weight > 40 kg) with relapsing remitting multiple sclerosis (ms) (please refer to section 5. 1 of the smpc for important information on the population for which efficacy has been established).
teriflunomide accord
accord healthcare s.l.u. - teriflunomide - stwardnienie rozsiane, Рецидивно-znika - leki immunosupresyjne selektywne leki immunosupresyjne - teriflunomide accord is indicated for the treatment of adult patients and paediatric patients aged 10 years and older with relapsing remitting multiple sclerosis (ms) (please refer to section 5. 1 for important information on the population for which efficacy has been established).
dapagliflozin viatris
viatris limited - dapagliflozin - diabetes mellitus, type 2; heart failure, systolic; heart failure; renal insufficiency, chronic - leki stosowane w cukrzycy - type 2 diabetes mellitusdapagliflozin viatris is indicated in adults and children aged 10 years and above for the treatment of insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise- as monotherapy when metformin is considered inappropriate due to intolerance. - in addition to other medicinal products for the treatment of type 2 diabetes. for study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied, see sections 4. 4, 4. 5 i 5. heart failuredapagliflozin viatris is indicated in adults for the treatment of symptomatic chronic heart failure with reduced ejection fraction. chronic kidney diseasedapagliflozin viatris is indicated in adults for the treatment of chronic kidney disease.